Literature DB >> 15511660

Regulatory CD4+ T cells and the control of autoimmune disease.

David C Wraith1, Kirsty S Nicolson, Nathaniel T Whitley.   

Abstract

The immune system is a delicately balanced network of interacting cells. In recent years, the concept of immune regulation/suppression has been firmly established, and both natural and induced regulatory cells play vital roles in protection from autoimmune disease. Recent work has revealed the diverse nature of regulatory CD4+ T (Treg) cells and the molecules involved in their function. Innate and adaptive responses to infection are able to override the suppressive properties of such regulatory cells, whereas several reports point to deficiencies in regulatory cell function in autoimmune disease. Protocols have been developed that allow the expansion of Treg cells in vitro and their antigen-specific induction in vivo. A full understanding of Treg differentiation and function will facilitate the development of improved strategies for prevention and treatment of autoimmune diseases.

Entities:  

Mesh:

Year:  2004        PMID: 15511660     DOI: 10.1016/j.coi.2004.09.015

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  29 in total

1.  Requirements for induction and maintenance of peripheral tolerance in stringent allograft models.

Authors:  Masayuki Sho; Koji Kishimoto; Hiroshi Harada; Mauren Livak; Alberto Sanchez-Fueyo; Akira Yamada; Xin Xiao Zheng; Terry B Strom; Giacomo P Basadonna; Mohamed H Sayegh; David M Rothstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

2.  Antigen-induced IL-10+ regulatory T cells are independent of CD25+ regulatory cells for their growth, differentiation, and function.

Authors:  Kirsty S Nicolson; Emma J O'Neill; Anette Sundstedt; Heather B Streeter; Sophie Minaee; David C Wraith
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

3.  Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Francisco O'Valle; Mario Delgado
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Natural and induced regulatory T cells: targets for immunotherapy of autoimmune disease and allergy.

Authors:  Kirsty S Nicolson; David C Wraith
Journal:  Inflamm Allergy Drug Targets       Date:  2006-09

5.  Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells.

Authors:  Badiga Venkata Aruna; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

6.  Genistein modulates the expression of Toll-like receptors in experimental autoimmune encephalomyelitis.

Authors:  Alyria Teixeira Dias; Sandra Bertelli Ribeiro de Castro; Caio César de Souza Alves; Marcilene Gomes Evangelista; Luan Cristian da Silva; Daniele Ribeiro de Lima Reis; Marco Antonio Machado; Maria Aparecida Juliano; Ana Paula Ferreira
Journal:  Inflamm Res       Date:  2018-04-23       Impact factor: 4.575

7.  Cholecystokinin octapeptide exerts its therapeutic effects on collagen-induced arthritis by suppressing both inflammatory and Th17 responses.

Authors:  Qiaoxia Li; Bin Cong; Baoen Shan; Jingge Zhang; Haiying Chen; Tao Wang; Chunling Ma; Jin Qin; Di Wen; Feng Yu
Journal:  Rheumatol Int       Date:  2010-04-08       Impact factor: 2.631

Review 8.  Anti-cytokine vaccines and the immunotherapy of autoimmune diseases.

Authors:  David C Wraith
Journal:  Eur J Immunol       Date:  2006-11       Impact factor: 5.532

9.  Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors.

Authors:  Maria I Christodoulou; Efstathia K Kapsogeorgou; Niki M Moutsopoulos; Haralampos M Moutsopoulos
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

10.  Immunotherapy with allergen peptides.

Authors:  Mark Larché
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.